InvestorsHub Logo
Followers 1
Posts 287
Boards Moderated 0
Alias Born 03/14/2016

Re: Jimmy Joe post# 46902

Monday, 03/14/2016 3:32:36 PM

Monday, March 14, 2016 3:32:36 PM

Post# of 144813
Now that the therapeutic potential of marijuana has been realized in a Phase 3 clinical trial, it could add value to PMCB. It's great to have a promising target for pancreatic cancer, but a pipeline with multiple strategies is more desirable. According to PMCB's own website : "In May 2014 PharmaCyte Biotech entered into a research agreement with the University of Northern Colorado (UNC) to perform initial research that will be necessary for the development of cannabinoid-based treatments for serious cancers. The UNC is working to identify a cell type that is capable of converting cannabinoid-like prodrugs into their cancer-killing forms." For now, I realize that the focus will be on pancreatic cancer and ifosfamide using CIAB, but breakthroughs with the use of cannabinoids may spur some added emphasis on this avenue.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News